Building a shared AL vs. ATTR diagnostic pathway
From touchPODCAST · 15:26
Show by touchpodcast
Listen to our expert faculty explore a shared diagnostic pathway for cardiac amyloidosis, including clinical and imaging red flags, monoclonal-protein testing, and the role of biopsy and amyloid typing. They also explore multidisciplinary collaboration and when to prioritize ruling out amyloid light-chain amyloidosis (AL). The multidisciplinary team: Cardiologist – Dr. Christian Nitsche, Medical University of Vienna, Vienna, Austria Hematologist – Dr. Yawara Kawano, Kumamoto University Hospital, Kumamoto City, Japan Amyloidosis specialist with a renal focus – Dr. Paolo Milani, University of Pavia, Pavia, Italy This touchPODCAST is for healthcare professionals outside of the UK. This activity is supported by an independent medical education grant from Alexion Pharma GmbH. Jointly provided by Partners for Advancing Clinical Education and touchIME. touchIME is an EBAC® accredited provider. For further information, please visit our websites: touchHEMATOLOGY, touchCARDIO and touchNEPHROLOGY
More episodes
- touchMDT – Recognizing TGCT earlier: Improving clinical recognition
- touchMDT – Beyond tumor control: Long-term multidisciplinary management of TGCT
- touchMDT – Beyond tumor control: Long-term management, recurrence and survivorship in TGCT
- Minimizing risk and maximizing care in metastatic breast cancer: A deep dive into ADC safety
- Presbyopia-correcting IOL decision-making: Answering the challenging clinical questions
- From first-line to next-gen: Tailoring hormonal contraception to the individual patient
- Glycogen storage disease type Ia: From pathophysiology to multidisciplinary management
- Integrating emerging AL therapies into real‑world MDT decisions
- Operationalizing the cardiac amyloidosis MDT
- touchEXPERT FOCUS - Integrating EGFR-directed strategies into early-stage NSCLC care
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.